Dr. Cecil B. Pickett joins the GVK Biosciences Scientific Advisory Board
GVK Biosciences (GVK BIO), Asia’s leading integrated research services organization announced the appointment of Dr. Cecil B. Pickett as Scientific Advisor to the Board of Directors.
Press Release (PressBurner) Dec 21, 2009 - Cecil B. Pickett, Ph.D. has served as President of Research and Development, and member of the Biogen Idec Board of Directors for three years (March 2006-October 2009). Prior to joining Biogen Idec, Dr. Pickett held several senior R&D positions at Schering-Plough Corporation. As the Senior Vice President & President, Schering-Plough Research Institute, Dr. Pickett helped bring several large and small molecule candidates into the Schering-Plough clinical development pipeline. Prior to joining Schering-Plough, he held several senior R&D positions at Merck & Company.
D.S.Brar, Chairman, GVK Biosciences, commented “Dr. Pickett is an acknowledged scientific leader and brings vast knowledge and experience regarding the interests and demands of pharmaceutical and biotech customers to our Scientific Advisory Board. His experience in drug metabolism, molecular pharmacology and expertise in leading drug discovery initiatives, will be invaluable to GVK BIO as we build our organization to provide a wide range of scientific solutions globally”.
Dr. Pickett commented “GVK Biosciences is a leader in contract research services and has built a strong and capable management & scientific team. I am excited to participate in GVK Biosciences growth strategies and look forward to contributing to the scientific advancement and development of GVK BIO”.
Dr. Pickett received his B.S. in Biology from California State University, Hayward, Calif., and his Ph.D. in Cell Biology from the University of California, Los Angeles (UCLA).
Dr. Pickett has served as a member of the U.S. Food and Drug Administration (FDA) Science Board, the Advisory Committee to the Director of the National Institutes of Health and The National Cancer Policy Board of the Institute of Medicine. He has served as a member of the National Academies Committee on Science, Engineering and Public Policy and a member of the Institute of Medicine Forum on Drug Discovery, Development and Translation. He also sits on the Board of Directors with Zimmer Holdings Inc, was elected to the Institute of Medicine of the National Academy of Sciences in 1993 and also is a member of The American Society for Cell Biology, American Society of Biochemistry & Molecular Biology, American Association for Cancer Research, and the American Association for the Advancement of Science.